Technology
Health
Pharmaceutical

EyePoint Pharmaceuticals

$2.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-1.21%) Today
-$0.03 (-1.21%) Today

Why Robinhood?

You can buy or sell EYPT and other stocks, options, ETFs, and crypto commission-free!

About

EyePoint Pharmaceuticals, Inc. Common Stock, also called EyePoint Pharmaceuticals, is a biopharmaceutical company. Read More It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Employees
44
Headquarters
Watertown, Massachusetts
Founded
1987
Market Cap
233.90M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
520.30K
High Today
$2.46
Low Today
$2.33
Open Price
$2.41
Volume
107.64K
52 Week High
$3.94
52 Week Low
$1.05

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
US
North America
Female CEOs

News

The Motley FoolMar 14

EYEPOINT PHARMACEUTICALS INC (EYPT) Q2 2019 Earnings Conference Call Transcript

EYEPOINT PHARMACEUTICALS INC (NASDAQ:EYPT) Q2 2019 Earnings Conference Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning. My name is Amanda, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharma's Fiscal Period Ended December 31st, 2018 Financial Results Conference Call. There will be a question-and-answer session to follow at the completion of the prepared rema...

110
MarketBeatMar 3

Stock Price, News, & Analysis for Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials. It also offers Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for...

74

Earnings

-$0.91
-$0.64
-$0.38
-$0.11
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
-$0.14 per share
Actual
-$0.12 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.